Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an open-label, single-centre, phase 2 trial
Andrea B. Apolo, Rosa Nadal, Yusuke Tomita, Nicole N. Davarpanah, Lisa M. Cordes, Seth M. Steinberg, Liang Cao, Howard L. Parnes, Rene Costello, Maria J. Merino, Les Folio, Liza Lindenberg, Mark Raffeld, Jeffrey Lin, Min-Jung Lee, Sunmin Lee, Sylvia V. Alarcon, Akira Yuno, Nancy A. Dawson, Kimaada Allette, Arpita Singha Roy, Dinuka De Silva, Molly M. Lee, Tristan M. Sissung, William D. Figg, Piyush K. Agarwal, John J Wright, Yang‐Min Ning, James L. Gulley, William L. Dahut, Donald P. Bottaro, Jane B. Trepel
Topics & Concepts
CabozantinibMetastatic Urothelial CarcinomaMedicineResponse Evaluation Criteria in Solid TumorsOncologyInternal medicineCohortClinical endpointRefractory (planetary science)Progressive diseaseCancerUrologyChemotherapyClinical trialBladder cancerUrothelial carcinomaPhysicsAstrobiologyBladder and Urothelial Cancer TreatmentsPhagocytosis and Immune RegulationCancer Immunotherapy and Biomarkers